BridgeMD
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS)
EU CTIS ID: 2024-515740-23-00
What this study is testing
The main goal of this study is to compare whether BMS-986489 FDC, when used with chemotherapy medicines helps people live longer compared with people who take chemotherapy medicines and atezolizumab.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of ES-SCLC
- Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
- At least one tumour that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system.
You likely can't join if
- People have already received certain types of treatment for extensive stage small cell lung cancer.
- People have certain health conditions, like spread of small cell lung cancer to the brain and meninges that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy.
The study team makes the final eligibility decision.
Where it's taking place
- Argentina
- Brazil
- Mexico
- Japan
- Korea, Republic of
- Canada
- Turkey
- India
- China
- Malaysia
- United Kingdom
- United States
- Switzerland
- Australia
- Chile
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Argentina; Brazil; Mexico; Japan; Korea, Republic of; Canada and 9 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.